Lanean...
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very effectively reversed thrombotic microangiopathy and reduced mortality and morbidity. Initial guidelines suggested lifelong treat...
Gorde:
| Argitaratua izan da: | Pediatr Nephrol |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer Berlin Heidelberg
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6794245/ https://ncbi.nlm.nih.gov/pubmed/30402748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-018-4091-3 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|